- Home
- ACI vs QGEN Comparison
ACI vs QGEN Comparison
Compare ACI & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACI
- QGEN
- Stock Information
- Founded
- ACI 1860
- QGEN 1986
- Country
- ACI United States
- QGEN Netherlands
- Employees
- ACI N/A
- QGEN N/A
- Industry
- ACI Food Chains
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACI Consumer Staples
- QGEN Health Care
- Exchange
- ACI Nasdaq
- QGEN Nasdaq
- Market Cap
- ACI 12.2B
- QGEN 9.9B
- IPO Year
- ACI 2020
- QGEN 1996
- Fundamental
- Price
- ACI $22.43
- QGEN $40.04
- Analyst Decision
- ACI Buy
- QGEN Buy
- Analyst Count
- ACI 12
- QGEN 8
- Target Price
- ACI $23.85
- QGEN $49.79
- AVG Volume (30 Days)
- ACI 8.5M
- QGEN 1.1M
- Earning Date
- ACI 04-15-2025
- QGEN 04-28-2025
- Dividend Yield
- ACI 2.67%
- QGEN 3.31%
- EPS Growth
- ACI N/A
- QGEN N/A
- EPS
- ACI 1.78
- QGEN 0.38
- Revenue
- ACI $79,930,900,000.00
- QGEN $1,978,214,000.00
- Revenue This Year
- ACI $2.35
- QGEN $5.15
- Revenue Next Year
- ACI $2.44
- QGEN $6.49
- P/E Ratio
- ACI $12.61
- QGEN $103.78
- Revenue Growth
- ACI 0.97
- QGEN 0.66
- 52 Week Low
- ACI $17.00
- QGEN $37.63
- 52 Week High
- ACI $22.59
- QGEN $47.93
- Technical
- Relative Strength Index (RSI)
- ACI 64.97
- QGEN 51.72
- Support Level
- ACI $20.66
- QGEN $39.31
- Resistance Level
- ACI $22.05
- QGEN $40.27
- Average True Range (ATR)
- ACI 0.45
- QGEN 0.55
- MACD
- ACI 0.10
- QGEN 0.16
- Stochastic Oscillator
- ACI 91.95
- QGEN 82.59
About ACI Albertsons Companies Inc.
Albertsons is the second largest supermarket operator in the United States with more than 2,200 stores across a variety of banners. About 80% of the firm's sales stem from non-perishable and fresh food, of which 25% comes from its portfolio of private brands. The company operates fuel centers and pharmacies at about 20% and 75% of its store locations, respectively. Albertsons went public in 2020 following years of ownership under private equity firm Cerberus Capital Management, which still owns about a fourth of outstanding shares.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).